- Home
- VMEO vs EBS Comparison
VMEO vs EBS Comparison
Compare VMEO & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- EBS
- Stock Information
- Founded
- VMEO 2004
- EBS 1998
- Country
- VMEO United States
- EBS United States
- Employees
- VMEO N/A
- EBS N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- EBS Health Care
- Exchange
- VMEO Nasdaq
- EBS Nasdaq
- Market Cap
- VMEO 652.9M
- EBS 529.9M
- IPO Year
- VMEO N/A
- EBS 2006
- Fundamental
- Price
- VMEO $7.83
- EBS $10.08
- Analyst Decision
- VMEO Hold
- EBS Strong Buy
- Analyst Count
- VMEO 4
- EBS 2
- Target Price
- VMEO $6.81
- EBS $13.50
- AVG Volume (30 Days)
- VMEO 1.5M
- EBS 1.4M
- Earning Date
- VMEO 10-28-2025
- EBS 10-29-2025
- Dividend Yield
- VMEO N/A
- EBS N/A
- EPS Growth
- VMEO N/A
- EBS N/A
- EPS
- VMEO 0.00
- EBS 1.35
- Revenue
- VMEO $416,596,000.00
- EBS $788,900,000.00
- Revenue This Year
- VMEO $2.98
- EBS N/A
- Revenue Next Year
- VMEO $4.96
- EBS $15.42
- P/E Ratio
- VMEO $2,378.13
- EBS $7.52
- Revenue Growth
- VMEO N/A
- EBS N/A
- 52 Week Low
- VMEO $3.64
- EBS $4.02
- 52 Week High
- VMEO $7.90
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- VMEO 79.39
- EBS 51.64
- Support Level
- VMEO $7.76
- EBS $9.91
- Resistance Level
- VMEO $7.82
- EBS $10.51
- Average True Range (ATR)
- VMEO 0.03
- EBS 0.79
- MACD
- VMEO -0.06
- EBS -0.05
- Stochastic Oscillator
- VMEO 90.00
- EBS 22.20
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.